Skip to main content

Articles

Page 6 of 42

  1. Glycaemic control of Type 1 Diabetes Mellitus (T1DM) remains a challenge due to hypoglycaemic episodes and the burden of insulin self-management. Advancements have been made with the development of automated i...

    Authors: Amanda Godoi, Isabela Reis Marques, Eduardo M. H. Padrão, Ashwin Mahesh, Larissa C. Hespanhol, José Eduardo Riceto Loyola Júnior, Isabela A. F. de Souza, Vittoria C. S. Moreira, Caroliny H. Silva, Isabele A. Miyawaki, Christi Oommen, Cintia Gomes, Ariadne C. Silva, Kavita Advani and Joao Roberto de Sa
    Citation: Diabetology & Metabolic Syndrome 2023 15:190
  2. Epicardial adipose tissue (EAT) is a type of ectopic fat with endocrine and paracrine functions. Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that responds to environmental stimul...

    Authors: Yu-Cheng Cheng, Wei-Chun Ma, Yu-Hsuan Li, Junyi Wu, Kae-Woei Liang, Wen-Jane Lee, Hsiu-Chen Liu, Wayne Huey-Herng Sheu and I-Te Lee
    Citation: Diabetology & Metabolic Syndrome 2023 15:188
  3. The associations between the triglyceride–glucose (TyG) index with subsequent stroke in American adults are unknown. The aim of this study was to determine the associations between baseline and trajectories of...

    Authors: Xinyi Wang, Qiyu Liu, Tongxin Wang, Wende Tian, Xuanye Chen, Jie Zhang, Qiuyi Li, Dan Ma, Lin Zhao, Zhuo Chen, Hao Xu and Keji Chen
    Citation: Diabetology & Metabolic Syndrome 2023 15:187
  4. Heart failure is closely correlated with diabetic cardiomyopathy (DCM) and can lead to mortality. Celastrol has long been utilized for the treatment of immune and inflammatory disorders. However, whether celas...

    Authors: Xuyong Zhao, Bingwu Huang, Jianhua Zhang, Wenjun Xiang and Ning Zhu
    Citation: Diabetology & Metabolic Syndrome 2023 15:186
  5. This study aimed to determine the association between glycemic variability (GV) and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).

    Authors: Salma Ali El Chab Parolin, Rebecca Benicio Stocco, Julia do Carmo Kneipp Lopes, Marcos Roberto Curcio Pereira, Milena Massae Yamashita, Maria Eduarda Domareski Goulart, Henrique Demeneck, Marcia Olandoski, Larissa Hermann de Souza Nunes, Victor Keniche Morisawa, Luiz Augusto Fanhani Cracco, Isabela Busto Silva, Jarbas Silva Motta Júnior, Daniela Veit Barreto, Gustavo Lenci Marques, Thyago Proença de Moraes…
    Citation: Diabetology & Metabolic Syndrome 2023 15:185
  6. Although the effect of Vitamin D Supplementation (Vit D) on several chronic diseases has been well conceded, its role in diabetes remains ambiguous. The present study investigated the interactive effects of Ae...

    Authors: Zahra Hoseini, Nasser Behpour and Rastegar Hoseini
    Citation: Diabetology & Metabolic Syndrome 2023 15:184
  7. The association between composite dietary antioxidant index (CDAI) and diabetes remains unknown. Our study was to investigate the association of CDAI with diabetes.

    Authors: Xiaojie Chen, He Lu, Yingwei Chen, Haiqiang Sang, Yi Tang and Yifan Zhao
    Citation: Diabetology & Metabolic Syndrome 2023 15:183
  8. Lipodystrophies are a heterogeneous group of diseases characterized by the selective loss of subcutaneous adipose tissue and ectopic fat deposition in different organs, including the liver. This study aimed to...

    Authors: Luiz F. Viola, Cynthia M. Valerio, João M. Araujo-Neto, Fabio F. Santos, Felipe Matsuura, Rodrigo O. Moreira and Amélio F. Godoy-Matos
    Citation: Diabetology & Metabolic Syndrome 2023 15:182
  9. The triglyceride and glucose (TyG) index has been considered a simple surrogate marker of insulin resistance, related to a high risk of mortality. However, few studies have investigated the specific relationsh...

    Authors: Haiyu Li, Yaohui Jiang, Xin Su and Zhe Meng
    Citation: Diabetology & Metabolic Syndrome 2023 15:181
  10. C-reactive protein(CRP), is an inflammatory marker that weaken leptin bioavailability and insulin sensitivity to disturb energy and glucose metabolism. Polycystic ovary syndrome (PCOS) exhibit a metabolic comp...

    Authors: Ke Li, Lingling Hu, Xinrun Li, Zhibin Yuan, Jia He, Dongfang Liu, Gangyi Yang and Lei Yuan
    Citation: Diabetology & Metabolic Syndrome 2023 15:180
  11. Type 2 diabetes (T2D) is a metabolic disease caused by the development of insulin resistance (IR), relative insulin deficiency, and hyperglycemia. Hyperglycemia-induced neurochemical dysregulation activates th...

    Authors: Nahi Sabih Alruwaili, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Amany E. Ragab, Ahmad Awad Alenazi, Athanasios Alexiou, Marios Papadakis and Gaber El-Saber Batiha
    Citation: Diabetology & Metabolic Syndrome 2023 15:179
  12. To evaluate the association of atherosclerotic cardiovascular disease (ASCVD) risk factors with incident ASCVD events among type 2 diabetes (T2D) individuals with microvascular complications.

    Authors: Yaxin Wang, Gabriella Bulloch, Yu Huang, Yingying Liang, Zijing Du, Guanrong Wu, Ying Fang, Yijun Hu, Xianwen Shang, Zhuoting Zhu, Xiayin Zhang, Xiaohong Yang and Honghua Yu
    Citation: Diabetology & Metabolic Syndrome 2023 15:178
  13. Central insulin resistance contributes to glaucoma development. Given the close association between metabolic syndrome MetS and insulin resistance, this study aimed to determine whether MetS is associated with...

    Authors: Jun-Hyuk Lee, Yu-Jin Kwon, Sung Jin Kim and Boyoung Joung
    Citation: Diabetology & Metabolic Syndrome 2023 15:177
  14. Age is a major risk factor associated with the complexity of coronary artery disease (CAD), and the prognosis of elderly patients with coronary heart disease is relatively poor. Metabolic disturbances are prev...

    Authors: Xiaona wang, Xinqiang Ji, Jianhui yu and Fan wang
    Citation: Diabetology & Metabolic Syndrome 2023 15:176
  15. There are studies on the nutritional status of type 2 diabetes (T2D), but there are no large cohort studies on the prognosis of Controlling Nutritional Status (CONUT) score for T2D. The aim of this study was t...

    Authors: Dikang Pan, Julong Guo, Zhixiang Su, Jingyu Wang, Sensen Wu, Jianming Guo and Yongquan Gu
    Citation: Diabetology & Metabolic Syndrome 2023 15:175
  16. The studies of the effect of diabetes on the stiffness of Achilles tendon (AT) tissue remain inconclusive, we believe it is necessary to find a reliable method which can be used to detect the stiffness changes...

    Authors: Xinxin Huang, Xingyu Chen, Xiu Chen, Ping Chi, Pengfei Wang, Xiaomei Zhan, Chunpeng Zou, Liang Wang and Yanyan Dong
    Citation: Diabetology & Metabolic Syndrome 2023 15:174
  17. To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s per...

    Authors: Ran Wei, Weihao Wang, Xiusheng Huang, Jingtao Qiao, Jinghe Huang, Chang Xing, Qi Pan and Lixin Guo
    Citation: Diabetology & Metabolic Syndrome 2023 15:173
  18. Patient navigation helps with better adherence to treatment, as well as better knowledge about diabetes and greater interest in performing, monitoring, and seeking health care. Therefore, this study aims to ev...

    Authors: Luciana Foppa, Betina Nemetz, Rosimeri de Matos, Josiane Schneiders, Gabriela Heiden Telo and Beatriz D. Schaan
    Citation: Diabetology & Metabolic Syndrome 2023 15:172
  19. Several observational cohorts and meta-analytical studies on humans have shown that users of sodium-glucose cotransporter-2 inhibitors (SGLT2is) have a lower risk for new-onset acute coronary syndrome (ACS) th...

    Authors: Tsung-Kun Lin, Mei-Chun Lee, Yu-Han Cheng, Timothy Ma, Mei-Chun Chen, Tsung-Yuan Yang and Gwo-Ping Jong
    Citation: Diabetology & Metabolic Syndrome 2023 15:170
  20. Higher fasting plasma glucose (FPG) levels were associated with an increased risk of all-cause mortality; however, the associations between long-term FPG trajectory groups and mortality were unclear, especiall...

    Authors: Wanlu Li, Chi Pang Wen, Wenyuan Li, Zhijun Ying, Sai Pan, Yizhan Li, Zecheng Zhu, Min Yang, Huakang Tu, Yi Guo, Zhenya Song, David Ta-Wei Chu and Xifeng Wu
    Citation: Diabetology & Metabolic Syndrome 2023 15:169
  21. C-peptide is considered a peptide with active function in the body, which can affect people’s health. However, the results of previous studies on the possible association of C-peptide with the risk of cardiome...

    Authors: Mitra Kazemi Jahromi, Hamid Ahmadirad, Sanaz Jamshidi, Hossein Farhadnejad, Ebrahim Mokhtari, Tahere Shahrokhtabar, Saeed Tavakkoli, Farshad Teymoori and Parvin Mirmiran
    Citation: Diabetology & Metabolic Syndrome 2023 15:168
  22. Obesity and metabolic syndromes are becoming increasingly prevalent worldwide. Insulin resistance (IR) is a common complication of obesity. However, IR occurrence varies across individuals with obesity and may...

    Authors: Yichen Cai, Pan Liu, Yumei Xu, Yuguo Xia, Xiaowan Peng, Haiyan Zhao and Qiu Chen
    Citation: Diabetology & Metabolic Syndrome 2023 15:167
  23. Diabetes mellitus is a global epidemic disease. Long-time exposure of patients to hyperglycemia can lead to various type of chronic tissue damage. Early diagnosis of and screening for diabetes are crucial to p...

    Authors: Lin Li, Yinlin Cheng, Weidong Ji, Mimi Liu, Zhensheng Hu, Yining Yang, Yushan Wang and Yi Zhou
    Citation: Diabetology & Metabolic Syndrome 2023 15:165
  24. We aimed to assess the association between the use of Glucagon-like peptide-1 receptor agonists and the risk of 12 respiratory diseases in patients with type 2 diabetes, obesity, or overweight.

    Authors: Meixin Yu, Ruxin Wang, Ling Pei, Xiaofang Zhang, Jinjing Wei, Yun Wen, Han Liu, Haowen Ye, Jinghao Wang and Lihong Wang
    Citation: Diabetology & Metabolic Syndrome 2023 15:164
  25. The goal of this study was to reproduce and evaluate the reliability of the network meta-analysis performed in the article “The best drug supplement for obesity treatment: A systematic review and network meta-...

    Authors: Xiaoxin Yu, Patrice L. Capers, Roger S. Zoh and David B. Allison
    Citation: Diabetology & Metabolic Syndrome 2023 15:163
  26. Patients with diabetes mellitus (DM) have cardiovascular diseases (CVD) as a major cause of mortality and morbidity. The primary purpose of this study was to assess the echocardiographic parameters that showed...

    Authors: Catia Cristina Silva Sousa Vergara Palma, Pablo Moura Lopes, Alfredo de Souza Bomfim and Marilia Brito Gomes
    Citation: Diabetology & Metabolic Syndrome 2023 15:162
  27. Diabetic cardiomyopathy (DC) is a serious heart disease caused by diabetes. It is unrelated to hypertension and coronary artery disease and can lead to heart insufficiency, heart failure and even death. Curren...

    Authors: Xuehua Yan, Yang Xie, Hongbing Liu, Meng Huang, Zhen Yang, Dongqing An and Guangjian Jiang
    Citation: Diabetology & Metabolic Syndrome 2023 15:161
  28. The management of antidiabetic therapy in people with type 2 diabetes (T2D) has evolved beyond glycemic control. In this context, Brazil and Portugal defined a joint panel of four leading diabetes societies to...

    Authors: Marcello Casaccia Bertoluci, Wellington S. Silva Júnior, Fernando Valente, Levimar Rocha Araujo, Ruy Lyra, João Jácome de Castro, João Filipe Raposo, Paulo Augusto Carvalho Miranda, Cesar Luiz Boguszewski, Alexandre Hohl, Rui Duarte, João Eduardo Nunes Salles, José Silva-Nunes, Jorge Dores, Miguel Melo, João Roberto de Sá…
    Citation: Diabetology & Metabolic Syndrome 2023 15:160
  29. Elevated fasting plasma glucose (FPG) levels can increase morbidity and mortality even when it is below the diagnostic threshold of type 2 diabetes mellitus (T2DM). We conducted a genome-wide DNA methylation a...

    Authors: Weijing Wang, Wenqin Yao, Qihua Tan, Shuxia Li, Haiping Duan, Xiaocao Tian, Chunsheng Xu and Dongfeng Zhang
    Citation: Diabetology & Metabolic Syndrome 2023 15:159
  30. Cognitive behavior therapy (CBT) has been applied in intervention research in diabetes patients with satisfying results. However, there was no research on type 2 diabetes (T2DM) patients with comorbidities. Th...

    Authors: Yanni Li, Nicholas Buys, Samantha Ferguson, Zhiyong Li, Yan-Chuan Shi, Li Li and Jing Sun
    Citation: Diabetology & Metabolic Syndrome 2023 15:158
  31. The metabolic score for insulin resistance (METS-IR) is a simple, convenient, and reliable marker for resistance insulin (IR), which has been regarded as a predictor of cardiovascular disease (CVD) and cardiov...

    Authors: Shuai Zhang, Zhenguo Wu, Yifan Zhuang, Xiangfei Sun, Juan Wang, Sha Chen, Dachuan Guo, Panpan Xu, Cheng Zhang and Jianmin Yang
    Citation: Diabetology & Metabolic Syndrome 2023 15:157
  32. Syndecan-4 (SDC4) is a member of the heparan sulfate proteoglycan family of cell-surface receptors. We and others previously reported that variation in the SDC4 gene was associated with several components of the ...

    Authors: Paolina Crocco, Denise Vecchie, Sreejit Gopalkrishna, Serena Dato, Giuseppe Passarino, Martin E. Young, Prabhakara R. Nagareddy, Giuseppina Rose and Maria De Luca
    Citation: Diabetology & Metabolic Syndrome 2023 15:156

    The Correction to this article has been published in Diabetology & Metabolic Syndrome 2023 15:166

  33. The risk for and treatment of cardiovascular disease (CVD) in type 2 diabetes (T2DM) is often incorrect and delayed. We wished to determine if a novel test improved physicians’ ability to risk stratify, diagno...

    Authors: John W. Peabody, David Paculdo, Enrico de Belen, Divya Ganesan, Isabella Cooney and Nelson Trujillo
    Citation: Diabetology & Metabolic Syndrome 2023 15:155
  34. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are commonly used in the management of type 2 diabetes mellitus (T2DM) and have been found to worsen the reduction of skeletal muscle mass in individuals with...

    Authors: Xudong Yang, Lifeng Wang, Liangzhi Zhang, Xia Zhai, Xiusheng Sheng, Helong Quan and Hengjun Lin
    Citation: Diabetology & Metabolic Syndrome 2023 15:154

    The Correction to this article has been published in Diabetology & Metabolic Syndrome 2023 15:171

  35. Authors: Morteza Izadi, Mohammad Javanbakht, Ali Sarafzadeh, Behzad Einollahi, Farzaneh Futuhi, Zahra Vahedi, Shi Zhao, Nematollah Jonaidi‑Jafari, Mahboobeh Sadat Hosseini, Javad Hosseini Nejad, Effat Naeimi, Seyed Hassan Saadat, Hadi Esmaeili Gouvarchin Ghaleh, Mozhgan Fazel, Zahra Einollahi and Luca Cegolon
    Citation: Diabetology & Metabolic Syndrome 2023 15:153

    The original article was published in Diabetology & Metabolic Syndrome 2023 15:140

  36. Recent studies have shown that the addition of sodium-glucose co-transporter 2 (SGLT2) inhibitors gradually reduces the estimated fluid volume parameters in a broad range of patient populations, suggesting tha...

    Authors: Atsushi Tanaka, Takumi Imai, Shigeru Toyoda, Kazuhiro Sugimoto, Ruka Yoshida, Machi Furuta and Koichi Node
    Citation: Diabetology & Metabolic Syndrome 2023 15:152
  37. Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk. Br...

    Authors: Mulualem Tesfaye Birhan, Teklie Mengie Ayele, Fikire Wondimu Abebe and Fiseha Nigussie Dgnew
    Citation: Diabetology & Metabolic Syndrome 2023 15:151
  38. Type 2 diabetes mellitus is one of the most common causes of chronic kidney disease (CKD) worldwide and prevalence of 1.75 per 100 inhabitants in Colombia. The aim of this study was to describe the treatment p...

    Authors: Manuel E Machado-Duque, Andres Gaviria-Mendoza, Luis F Valladales-Restrepo, Juan Sebastian Franco, Maria de Rosario Forero, David Vizcaya and Jorge E Machado-Alba
    Citation: Diabetology & Metabolic Syndrome 2023 15:150
  39. Exosomes from adipose-derived stem cells (ADSCs-Exos) have exhibited a therapeutic role in diabetic nephropathy (DN). Further studies are needed to investigate how ADSCs-Exos regulate oxidative stress and infl...

    Authors: Peiyao Ren, Fengmei Qian, Lanjun Fu, Wenfang He, Qiang He, Juan Jin and Danna Zheng
    Citation: Diabetology & Metabolic Syndrome 2023 15:149
  40. Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus (DM) that can cause annoying symptoms. To address this condition, several treatment approaches have been proposed, including s...

    Authors: Armin Nazeri, Ali Mohammadpour, Mohammad-Hadi Saeed Modaghegh and Mojtaba Kianmehr
    Citation: Diabetology & Metabolic Syndrome 2023 15:148
  41. This meta-analysis was conducted given the contradictory findings from studies on the influence of diabetes duration or age at onset on mortality in patients with insulin-dependent diabetes mellitus (IDDM).

    Authors: Xing-mu Wang, Shu-ping Zhong, Gang-feng Li and Fu-yuan Zhuge
    Citation: Diabetology & Metabolic Syndrome 2023 15:147
  42. Metabolomic signatures of type 2 diabetes mellitus (T2DM) in Tibetan Chinese population, a group with high diabetes burden, remain largely unclear. Identifying the serum metabolite profile of Tibetan T2DM (T-T...

    Authors: Jinli Meng, Fangfang Huang, Jing Shi, Chenghui Zhang, Li Feng, Suyuan Wang, Hengyan Li, Yongyue Guo, Xin Hu, Xiaomei Li, Wanlin He, Jian Cheng and Yunhong Wu
    Citation: Diabetology & Metabolic Syndrome 2023 15:146
  43. Prediabetes is a transitional state between normal blood glucose levels and diabetes, but it is also a reversible process. At the same time, as one of the most important tissues in the human body, the metaboli...

    Authors: Yu Tian, Dongxu Shi, Haiying Liao, Binan Lu and Zongran Pang
    Citation: Diabetology & Metabolic Syndrome 2023 15:145
  44. Type 1 diabetes mellitus (T1D) is a condition resulting from autoimmune destruction of pancreatic β cells, leading patients to require lifelong insulin therapy, which, most often, does not avoid the most common c...

    Authors: Marluce da Cunha Mantovani, Ilana Gabanyi, Carlos Andrés Pantanali, Vinícius Rocha Santos, Maria Lúcia Cardillo Corrêa-Giannella and Mari Cleide Sogayar
    Citation: Diabetology & Metabolic Syndrome 2023 15:144
  45. This study aimed to investigate the relationship between the TyG (Triglyceride-glucose index) and the prognosis of patients with HOCM (hypertrophic obstructive cardiomyopathy) without diabetes.

    Authors: Xiangbin Meng, Jun Gao, Kuo Zhang, Wen Jun, Jing-Jia Wang, Xu-Liang Wang, Yuan-Geng-Shuo Wang, Ji-Lin Zheng, Yu-Peng Liu, Jing-Jing Song, Jie Yang, Yi-Tian Zheng, Chen Li, Wen-Yao Wang, Chunli Shao and Yi-Da Tang
    Citation: Diabetology & Metabolic Syndrome 2023 15:143
  46. Acute myocardial infarction (AMI) is the most prevalent cause of mortality and morbidity in patients with type 2 diabetes mellitus (T2DM). However, strict blood glucose control does not always prevent the deve...

    Authors: Ning Cao, Yichun Wang, Boyi Bao, Man Wang, Jiayu Li, Wenxi Dang, Bing Hua, Lijin Song, Hongwei Li and Weiping Li
    Citation: Diabetology & Metabolic Syndrome 2023 15:142
  47. Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-g...

    Authors: Bin Feng, Peiran Yu, Hao Yu, Buyun Qian, Yuan Li, Kangyun Sun, Bimin Shi, Nannan Zhang and Guidong Xu
    Citation: Diabetology & Metabolic Syndrome 2023 15:141
  48. Percutaneous coronary intervention (PCI) is one of the most performed well-succeeded therapeutic procedures worldwide, reducing symptoms and improving quality of life. Neutrophil Gelatinase-associated Lipocali...

    Authors: Mateus Paiva Marques Feitosa, Eduardo Gomes Lima, Alexandre Antônio Cunha Abizaid, Roxana Mehran, Neuza Helena Moreira Lopes, Thiago de Assis Fischer Ramos, Alexandre Hideo-Kajita, Roberto Kalil Filho and Carlos Vicente Serrano Junior
    Citation: Diabetology & Metabolic Syndrome 2023 15:138

New Content Item

The official journal of the Brazilian Diabetes Society.

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.4
    5-year Journal Impact Factor: 4.1
    Source Normalized Impact per Paper (SNIP): 1.063
    SCImago Journal Rank (SJR): 1.147

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 87

    Usage 2023
    Downloads: 1,322,026
    Altmetric mentions: 1,058